Kaplan Fox & Kilsheimer LLP Encourages ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Investors to Contact the Firm Before October 5, 2026

A securities class action has been filed against ARS Pharmaceuticals on behalf of investors who bought shares between March 9 and June 24, 2026. The complaint centers on ARS's disclosure that neffy received no new commercial formulary additions or coverage decisions in the July 1 cycle; shares fell $2.52, or 23.9%, to $8.02 on June 25. Investors seeking lead-plaintiff status must apply by October 5, 2026.

Analysis

The litigation notice is not itself a fundamental catalyst; securities suits commonly follow a large single-day drawdown and have low near-term cash-flow relevance. The investable issue is whether neffy's reimbursement gap persists through the next payer decision windows: absent broad commercial coverage, prescription growth can lag demand indicators because patient out-of-pocket cost becomes the binding constraint. That raises the probability of lower net pricing, larger patient-support spend, and a longer cash-burn runway than a launch model built on rapid formulary conversion assumes.

Over the next 1-3 months, SPRY's valuation will be driven by independently verifiable access metrics—covered lives, formulary tier, prior-authorization requirements, gross-to-net deductions, and prescription fill persistence—not by litigation developments. A delayed coverage ramp would preserve incumbent injectable epinephrine economics, modestly favoring VTRS through its EpiPen franchise and generic alternatives, although the impact is unlikely to be material to VTRS consolidated estimates. The 6-18 month structural question remains whether needle-free administration expands the total anaphylaxis-treatment market enough to offset access friction; that requires evidence of repeat fills and school/employer adoption, not merely prescriptions written.

Contrarianly, the post-disappointment selloff could be overdone if formulary decisions were deferred administratively rather than rejected and the next cycle produces multiple large-plan wins. Conversely, the market may still be underestimating the financing risk if management responds with heavier rebates or commercial spend: weaker net revenue and slower uptake can force dilution before the product reaches self-funded scale. BAC and ALV are mentioned only in the law firm's historical marketing and have no actionable linkage.

Key Decisions for Investors

• No position solely on the class-action announcement; treat it as a legal aftershock rather than a new information event.
• Maintain a bearish SPRY watch bias into the next earnings/access update; consider a short only if reported covered lives or net-revenue guidance misses launch assumptions, with a stop on disclosed broad national-plan additions and improving refill data. The key downside mechanism is funding/dilution risk, not litigation damages.
• For a defined-risk bearish expression ahead of the next access disclosure, use SPRY put spreads rather than an outright short; size only after confirming option liquidity and implied volatility, which may already price elevated event risk.
• Monitor VTRS prescription and epinephrine-franchise commentary for incremental share-retention evidence, but do not establish a standalone VTRS long on this signal: any benefit is too small relative to company-wide generic-drug pricing and portfolio risks.
• Set an alert for the next commercial formulary cycle: multiple large-plan additions, favorable tier placement, and unchanged gross-to-net assumptions would falsify the near-term bearish thesis and could support a sharp SPRY short-covering move.